Gradient Investments LLC raised its stake in Amgen Inc. (NASDAQ:AMGN) by 1.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 30,739 shares of the medical research company’s stock after buying an additional 537 shares during the period. Gradient Investments LLC’s holdings in Amgen were worth $5,128,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of AMGN. Meag Munich Ergo Kapitalanlagegesellschaft MBH increased its position in Amgen by 99.1% in the second quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 102,511 shares of the medical research company’s stock valued at $15,583,000 after buying an additional 51,025 shares during the last quarter. Badgley Phelps & Bell Inc. increased its position in Amgen by 76.9% in the second quarter. Badgley Phelps & Bell Inc. now owns 49,799 shares of the medical research company’s stock valued at $7,577,000 after buying an additional 21,649 shares during the last quarter. Parsec Financial Management Inc. increased its position in Amgen by 2.2% in the second quarter. Parsec Financial Management Inc. now owns 86,538 shares of the medical research company’s stock valued at $13,167,000 after buying an additional 1,861 shares during the last quarter. Nationwide Fund Advisors increased its position in Amgen by 3.7% in the second quarter. Nationwide Fund Advisors now owns 631,839 shares of the medical research company’s stock valued at $96,134,000 after buying an additional 22,751 shares during the last quarter. Finally, PGGM Investments increased its position in Amgen by 9.7% in the second quarter. PGGM Investments now owns 725,684 shares of the medical research company’s stock valued at $110,413,000 after buying an additional 64,011 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Shares of Amgen Inc. (NASDAQ:AMGN) traded up 0.64% during mid-day trading on Tuesday, reaching $146.00. 2,934,575 shares of the company traded hands. Amgen Inc. has a 52 week low of $133.64 and a 52 week high of $176.85. The firm has a 50 day moving average of $151.01 and a 200-day moving average of $160.49. The stock has a market capitalization of $108.61 billion, a PE ratio of 14.61 and a beta of 1.15.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, October 27th. The medical research company reported $3.02 earnings per share for the quarter, topping the consensus estimate of $2.79 by $0.23. Amgen had a return on equity of 29.27% and a net margin of 33.63%. The business earned $5.81 billion during the quarter, compared to the consensus estimate of $5.73 billion. During the same period last year, the company earned $2.72 earnings per share. The business’s revenue for the quarter was up 1.5% compared to the same quarter last year. On average, equities research analysts expect that Amgen Inc. will post $11.56 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 8th. Stockholders of record on Wednesday, November 16th will be given a dividend of $1.00 per share. The ex-dividend date is Monday, November 14th. This represents a $4.00 annualized dividend and a dividend yield of 2.74%. Amgen’s dividend payout ratio (DPR) is 39.92%.

TRADEMARK VIOLATION NOTICE: “Amgen Inc. (AMGN) Shares Bought by Gradient Investments LLC” was posted by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was stolen and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be accessed at http://www.dailypolitical.com/2016/11/29/amgen-inc-amgn-shares-bought-by-gradient-investments-llc.html.

Several equities analysts recently commented on the stock. Credit Suisse Group AG set a $206.00 price objective on shares of Amgen and gave the company a “buy” rating in a research note on Saturday, September 17th. Leerink Swann reaffirmed a “hold” rating on shares of Amgen in a research note on Saturday, September 17th. RBC Capital Markets set a $190.00 price objective on shares of Amgen and gave the company a “buy” rating in a research note on Sunday, October 30th. Jefferies Group reaffirmed a “buy” rating on shares of Amgen in a research note on Wednesday, August 3rd. Finally, Argus reaffirmed a “buy” rating and set a $195.00 price objective (up previously from $185.00) on shares of Amgen in a research note on Friday, August 5th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $182.04.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).

5 Day Chart for NASDAQ:AMGN

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.